News
-
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website -
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Xenetic Biosciences, Inc. collaborates with PeriNess Ltd. on a clinical study at Tel-Aviv Sourasky Medical Center to evaluate DNase I candidate XBIO-015 in osteosarcoma and Ewing sarcoma patients -
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Xenetic Biosciences reports encouraging preclinical data on DNase-based technology targeting NETosis for difficult cancers. Focus on clinical studies partnerships and DNase I development program for pancreatic carcinoma -